Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
TNO155 - SHP2 Inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
NCT03114319 (CTNO155X2101)
Solid tumors (single agent)
Phase 1
255
Number of participants with adverse events
Number of participants with dose limiting toxicities
Arms Intervention
Drug: TNO155
Drug: TNO155 in combination with EGF816 (nazartinib)
Adult patients with advanced solid tumors in selected indications
NCT04000529 (CTNO155B12101)
Solid tumors (combo)
Phase 1
126
Incidence of dose limiting toxicities (DLTs) during the first cycle of combination
treatment during the dose escalation part
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
as per CTCAE v5.0, by treatment
Dose tolerability
TNO155 and Spartalizumab (PDR001)
TNO155 and Ribociclib (LEE011)
Patients with advanced malignancies
Target Patients
Read-out Milesstone(s)
2023
Publication
TBD
117 Investor Relations | Q2 2021 Results
2022
TBD
NOVARTIS | Reimagining MedicineView entire presentation